Cna Financial Corp Adc Therapeutics Sa Transaction History

Cna Financial Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$4.66 - $10.31 $7,316 - $16,186	-1,570 Reduced 10.12%	13,945 $67,000
Q1 2022 May 10, 2022	BUY	$13.28 - $20.03 $3,585 - $5,408	270 Added 1.77%	15,515 $228,000
Q4 2021 Feb 11, 2022	BUY	$19.29 - $31.51 $8,487 - $13,864	440 Added 2.97%	15,245 $308,000
Q3 2021 Nov 12, 2021	SELL	$20.45 - $30.0 $45,399 - $66,600	-2,220 Reduced 13.04%	14,805 $402,000
Q2 2021 Aug 12, 2021	BUY	$20.38 - $27.04 $27,288 - $36,206	1,339 Added 8.54%	17,025 $415,000
Q1 2021 May 14, 2021	BUY	$22.75 - $34.05 $111,725 - $167,219	4,911 Added 45.58%	15,686 $383,000
Q4 2020 Feb 12, 2021	BUY	$25.26 - $38.02 $93,209 - $140,293	3,690 Added 52.08%	10,775 $345,000
Q3 2020 Nov 12, 2020	BUY	$32.87 - $51.05 $72,971 - $113,331	2,220 Added 45.63%	7,085 $234,000
Q2 2020 Aug 13, 2020	BUY	$29.65 - $46.81 $144,247 - $227,730	4,865 New	4,865 $228,000

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $135M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.